Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

205.48
+0.08000.04%
Post-market: 205.480.00000.00%19:30 EDT
Volume:731.55K
Turnover:149.54M
Market Cap:10.76B
PE:-54.53
High:209.53
Open:207.58
Low:200.19
Close:205.40
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:1.34
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:129.20
PE(LYR):-55.81

Loading ...

Axsome Therapeutics shareholders elect Saad, Mahony as Class II directors

Reuters
·
Jun 10

Axsome Therapeutics CEO Herriot Tabuteau disposes of USD 11.97 million in common shares

Reuters
·
Jun 10

Axsome CFO Nick Pizzie sells 33,000 shares for $7.92 million

Reuters
·
Jun 10

What Axsome Therapeutics (AXSM)'s SUNOSI Patent Settlements and Migraine Updates Mean For Shareholders

Simply Wall St.
·
Jun 06

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (AMRX), Charles River Labs (CRL) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Jun 04

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

GlobeNewswire
·
Jun 04

BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway

Reuters
·
Jun 03

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 03

BUZZ-U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel Dynamics

Reuters
·
Jun 03

Axsome Therapeutics Reaches Settlement Over Sunosi Patent Dispute; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 03

BUZZ-Axsome Therapeutics rises after co resolves patent litigation for sleep disorder drug

Reuters
·
Jun 03

BRIEF-Axsome Therapeutics Announces Settlement Resolving All Sunosi® (Solriamfetol) Patent Litigation

Reuters
·
Jun 03

Axsome settles all Sunosi patent litigation, sets generic entry for 2040

Reuters
·
Jun 03

Axsome Therapeutics - Resolves All Patent Litigation Related to Sunosi

THOMSON REUTERS
·
Jun 03

Axsome Therapeutics - Five Companies Granted Right to Sell Generic Sunosi From 2040, Subject to FDA Approval

THOMSON REUTERS
·
Jun 03

Axsome Therapeutics - Enters Settlement Agreement With First-to-File Generic Applicant for Sunosi

THOMSON REUTERS
·
Jun 03

Axsome Therapeutics director Mark Coleman disposes of common shares worth $4.06 million

Reuters
·
Jun 03

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

GlobeNewswire
·
Jun 01

Axsome Therapeutics (AXSM) Valuation Check After Strong Recent Share Price Momentum

Simply Wall St.
·
May 31

Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says

MT Newswires Live
·
May 28